ABIONYX Pharma

Report Publication Announcement • Jan 23, 2019

Press release

2019 Financial agenda

Toulouse, FRANCE, Lakeland, UNITED-STATES, January 23, 2019, 6.00 pm CET – Cerenis Therapeutics (FR0012616852 – CEREN – PEA PME eligible), an international biopharmaceutical company dedicated to the discovery and development of HDL-based innovative therapies for treating cardiovascular and metabolic diseases, as well as new HDL-based vectors for targeted drug delivery in the field of oncology, today announces its financial agenda for 2019.

Events	Date*
▪ Cash position as of December 31, 2018	January 24, 2019
▪ 2018 Annual Results and update on activity	January 24, 2019
▪ Cash position and revenue for Q1 2019	April 18, 2019
▪ Cash position and revenue for Q2 2019	July 25, 2019
▪ 2019 Half Year Results	September 10, 2019
▪ Cash position and revenue for Q3 2019	October 24, 2019

*Indicative dates which may be subject to change. With some exceptions, press releases are distributed after the financial markets closure.

About CERENIS

Founded in 2005, Cerenis Therapeutics is an international biopharmaceutical company dedicated to the discovery and development of HDL-based innovative therapies. CERENIS' expertise has translated into a rich portfolio of programs for the treatment of cardiovascular disease and associated metabolic diseases such as NAFLD and NASH as well as a HDL targeted drug delivery platform in oncology, more specifically in immuno-oncology and chemotherapy.

Cerenis Cyrille Tupin Deputy CEO info@cerenis.com +33 (0)5 62 24 09 49 NewCap Investors relations Emmanuel Huynh / Louis-Victor Delouvrier cerenis@newcap.eu +33 (0)1 44 71 98 53

NewCap Media relations Nicolas Merigeau cerenis@newcap.eu +33 (0)1 44 71 94 98